Overview

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Status:
Not yet recruiting
Trial end date:
2028-12-16
Target enrollment:
Participant gender:
Summary
This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Cyclophosphamide
Doxorubicin
Lenalidomide
Prednisolone
Prednisone
Rituximab
Tisagenlecleucel
Vincristine